In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $75.00. The company’s ...

Shares of CRBP stock opened at $9.78 on Monday. The company’s fifty day simple moving average is $12.65 and its two-hundred day simple moving average is $27.00. Corbus Pharmaceuticals has a 52 ...

1 Day CRBP -2.32% DJIA -0.07% Russell 2K 0.00% Health Care/Life Sciences -0.02% ...

Shares of CRBP stock opened at $11.30 on Monday. Corbus Pharmaceuticals has a 52-week low of $5.67 and a 52-week high of $61.90. The stock has a market cap of $137.62 million, a price-to-earnings ...

Find the latest Corbus Pharmaceuticals Holdings CRBP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, dipping to $10.43. With a beta of 2.64 and a trading range of $7.49 to $61.90 over the past... ByInvesting.com ...

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released. The ...

1 Day CRBP -1.11% DJIA -0.75% Russell 2K -0.86% Health Care/Life Sciences 0.29% ...